Source: http://www.google.com/patents/US5726209?dq=7,292,151
Timestamp: 2017-05-23 00:20:45
Document Index: 378945675

Matched Legal Cases: ['art 2', 'art 2', 'art 1', 'art 1', 'art 2', 'art 2', 'art 1', 'art 1']

Patent US5726209 - Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsBiocompatible fluorocarbon emulsions are utilized to inhibit the removal of endogenously produced nitric oxide from the bloodstream, and to thereby inhibit vascular stenosis, vasoconstriction, and any other physiological condition or disorder arising in whole or in part from a deficiency of endogenous...http://www.google.com/patents/US5726209?utm_source=gb-gplus-sharePatent US5726209 - Liquid fluorocarbon emulsion as a vascular nitric oxide reservoirAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS5726209 APublication typeGrantApplication numberUS 08/501,976Publication dateMar 10, 1998Filing dateJun 7, 1995Priority dateJun 7, 1995Fee statusLapsedAlso published asCA2221965A1, CN1192136A, EP0831776A2, WO1996040058A2, WO1996040058A3Publication number08501976, 501976, US 5726209 A, US 5726209A, US-A-5726209, US5726209 A, US5726209AInventorsStephen F. Flaim, Jean G. RiessOriginal AssigneeAlliance Pharmaceutical Corp.Export CitationBiBTeX, EndNote, RefManPatent Citations (12), Non-Patent Citations (38), Referenced by (7), Classifications (11), Legal Events (14) External Links: USPTO, USPTO Assignment, EspacenetLiquid fluorocarbon emulsion as a vascular nitric oxide reservoir
US 5726209 AAbstract
The oxygen carrying capacity of liquid fluorocarbons has also led to their use as blood substitutes, and in partial liquid ventilation applications, wherein a subject animal or patient breathes oxygenated liquid fluorocarbon to deliver oxygen through the lungs to the bloodstream. Fluorocarbon emulsions have also been used in diagnostic imaging applications. Radiopaque fluorocarbon such as perfluorooctyl bromide (C8 F17 Br, "PFOB" or "perflubron") are useful for this purpose, with 1-bromoperfluoroctane being particularly prefered.
Although there have been no models developed to accurately predict the solubilities of gases in liquid fluorocarbon, the solubilities of gases generally increase with increasing molecular volume. Nitric oxide, therefore, should have a liquid fluorocarbon solubility intermediate between molecular oxygen (O2) and molecular nitrogen (N2). Based on molecular volume, the solubility of O2 may be estimated to be approximately 20 mM at 37 degrees C., while the solubility of N2 may be estimated to be approximately 14 mM. Nitric oxide, therefore, is likely to have a solubility of approximately 17 mM at 37 degrees C., which corresponds to approximately 38% v/v of a fluorocarbon/nitric oxide mixture.
A large number of various commercially available fluorocarbons and fluorocarbon combinations are known to make suitable emulsions. Monobrominated fluorocarbons such as perfluorooctylbromide (C8 F17 Br, "PFOB" or "perflubron"), 1-bromopentadecafluoroseptane (C7 F15 Br) , and 1-bromotridecafluorohexane (C6 F13 Br, perfluorohexylbromide, or "PFHB") are known to make suitable emulsions and are also known to have high oxygen solubility. Preferably, the fluorocarbon is present in the aqueous phase at approximately 5-125% weight in grams to emulsion volume in milliliters.
Increase in Rabbit Renal Blood Flow Following Perflubron Emulsion Injection
The figure illustrates the response of the rabbit renal blood flow to this second intravenous administration of liquid fluorocarbon emulsion. As can be seen in the Figure, emulsion alone produced a 60% increase in renal blood flow within 5 minutes and persisted for over 30 minutes. In contrast, the prior injection of L-NAME (NG -nitro-L-arginine methyl ester), a nitric oxide synthase inhibitor, reduced or eliminated the blood flow increase. This indicates sufficient fluorocarbon uptake of endogenous nitric oxide to increase nitric oxide stable half-life in the plasma, and thereby enhance nitric oxide induced renal vasodilation.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4781676 *Feb 20, 1987Nov 1, 1988Air Products And Chemicals, Inc.Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cellsUS4865836 *Jan 14, 1986Sep 12, 1989Fluoromed Pharmaceutical, Inc.Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transportUS4866096 *Mar 20, 1987Sep 12, 1989Air Products And Chemicals, Inc.Stable fluorochemical aqueous emulsionsUS4895876 *Mar 20, 1987Jan 23, 1990Air Products And Chemicals, Inc.Concentrated stable fluorochemical aqueous emulsions containing triglyceridesUS4927623 *Jan 4, 1988May 22, 1990Alliance Pharmaceutical Corp.Dissolution of gas in a fluorocarbon liquidUS4987154 *Aug 5, 1987Jan 22, 1991Alliance Pharmaceutical Corp.Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal useUS4993415 *Jul 12, 1990Feb 19, 1991Alliance Pharmaceutical Corp.Magnetic resonance imaging with perfluorocarbon hydridesWO1993002653A1 *Aug 5, 1992Feb 18, 1993Segel Leigh DFluorocarbon blood substituteWO1994000180A1 *Jun 25, 1993Jan 6, 1994The General Hospital CorporationMethods and devices for relaxing smooth muscle contractionsWO1994009625A2 *Oct 27, 1993May 11, 1994Alliance Pharmaceutical Corp.Stabilization of fluorocarbon emulsionsWO1995010267A1 *Oct 7, 1994Apr 20, 1995The United States Of America, Represented By The Secretary, Department Of Health And Human ServicesUse of nitric oxide-releasing compounds as hypoxic cell radiation sensitizersWO1995012394A1 *Oct 31, 1994May 11, 1995The United States Of America, Represented By The Secretary, Department Of Health And Human ServicesUse of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury* Cited by examinerNon-Patent CitationsReference1"Inhaled Nitric Oxide for the Adult Respiratory Distress Syndrome" New England J. of Medicine 329(3): 206-207 (1993).2"Perfluorochemical Blood Substitutes" Technical Information Ser. No. 5 (pp. 1-177) Jun. 30, 1978.3"Perfluorochemical Blood Substitutes" Technical Information Ser. No. 7 (pp. 1-119) Jul. 30, 1981.4Buddemeier, et al. "Oxygent® (Oxygen-Carrying Perfluorochemical Emulsion) Preserves Endothelial Dependent and Independent Vasodilator Responses After Experimental Myocardial Infarction and Reperfusion" Clinical Research Meeting Apr. 29-May 2, 1994.5 *Buddemeier, et al. Oxygent (Oxygen Carrying Perfluorochemical Emulsion) Preserves Endothelial Dependent and Independent Vasodilator Responses After Experimental Myocardial Infarction and Reperfusion Clinical Research Meeting Apr. 29 May 2, 1994.6Carter, et al. "Nitric Oxide Production is Intensely and Persistently Increased in Tissue by Thermal Injury" Biochem. J. 304: 201-204 (1994).7 *Carter, et al. Nitric Oxide Production is Intensely and Persistently Increased in Tissue by Thermal Injury Biochem. J. 304: 201 204 (1994).8Fazekas, et al. "Effect of Nitric Oxide Inhibition on Capsaicin-Elicited Vasodilation in the Rat Oral Circulation" Res. Esp. Med. 194: 357-365 (1994).9 *Fazekas, et al. Effect of Nitric Oxide Inhibition on Capsaicin Elicited Vasodilation in the Rat Oral Circulation Res. Esp. Med. 194: 357 365 (1994).10 *Inhaled Nitric Oxide for the Adult Respiratory Distress Syndrome New England J. of Medicine 329(3): 206 207 (1993).11Kinsella, et al. "Clinical Responses to Prolonged Treatment of Persistent Pulmonary Hypertension of the Newborn with Low Doses of Inhaled Nitric Oxide" J. of Pediatrics 123(1): 103-108 (1993).12 *Kinsella, et al. Clinical Responses to Prolonged Treatment of Persistent Pulmonary Hypertension of the Newborn with Low Doses of Inhaled Nitric Oxide J. of Pediatrics 123(1): 103 108 (1993).13Kovach, et al. "Effects of NG -Nitro-L-Arginine and L-Arginine on Regional Cerebral Blood Flow in the Cat" J. of Physiology 449: 183-196 (1992).14Kovach, et al. "Endothelial Dysfunction in Shock States" Am. Physiol. Soc. 8: 145-148 (1993).15 *Kovach, et al. Effects of N G Nitro L Arginine and L Arginine on Regional Cerebral Blood Flow in the Cat J. of Physiology 449: 183 196 (1992).16 *Kovach, et al. Endothelial Dysfunction in Shock States Am. Physiol. Soc. 8: 145 148 (1993).17 *Leach et al, Pediatric Research , vol. 35, No. 4 Part 2, Apr. 1994, p. 394A, abstract No. 2351.18Leach et al, Pediatric Research, vol. 35, No. 4 Part 2, Apr. 1994, p. 394A, abstract No. 2351.19Lefer, et al. "Antineutrophil and Myocardial Protecting Actions of a Novel Nitric Oxide Donor After Acute Myocardial Ischemia and Reperfusion in Dogs" Circulation 88(5 Part 1): 2337-2350 (1993).20Lefer, et al. "Microvascular Actions of Nitric Oxide Donors in Circulatory Disorders" Nitric Oxide Conference, Mar. 27-28, 1995 (8 pgs.).21 *Lefer, et al. Antineutrophil and Myocardial Protecting Actions of a Novel Nitric Oxide Donor After Acute Myocardial Ischemia and Reperfusion in Dogs Circulation 88(5 Part 1): 2337 2350 (1993).22 *Lefer, et al. Microvascular Actions of Nitric Oxide Donors in Circulatory Disorders Nitric Oxide Conference , Mar. 27 28, 1995 (8 pgs.).23Milner, Anthony D. "Nitric Oxide" Eur. J. Pediatr. 153 (Suppl 2): S7-S11 (1994).24 *Milner, Anthony D. Nitric Oxide Eur. J. Pediatr. 153 (Suppl 2): S7 S11 (1994).25 *Perfluorochemical Blood Substitutes Technical Information Ser. No. 5 (pp. 1 177) Jun. 30, 1978.26 *Perfluorochemical Blood Substitutes Technical Information Ser. No. 7 (pp. 1 119) Jul. 30, 1981.27Pinsky, et al. "The Role of Nitric Oxide in Cardiac Preservation for Transplantation" Circulation 88(4 Part 2): (1993).28 *Pinsky, et al. The Role of Nitric Oxide in Cardiac Preservation for Transplantation Circulation 88(4 Part 2): (1993).29Roberts, et al. "Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn" The Lancet 340:818-819 (1992).30 *Roberts, et al. Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn The Lancet 340:818 819 (1992).31Rubanyi, et al. "Cytoprotective Function of Nitric Oxide: Inactivation of Superoxide Radicals Produced by Human Leukocytes" Biochem. and Biophys. Res. Commun. 181(3): 1392-1397 (1991).32 *Rubanyi, et al. Cytoprotective Function of Nitric Oxide: Inactivation of Superoxide Radicals Produced by Human Leukocytes Biochem. and Biophys. Res. Commun. 181(3): 1392 1397 (1991).33Rubanyi, Gabor M. "The Role of Endothelium in Cardiovascular Homeostasis and Diseases" J. of Cardiovascular Pharmacology 22 (Suppl 4): S1-S14 (1993).34 *Rubanyi, Gabor M. The Role of Endothelium in Cardiovascular Homeostasis and Diseases J. of Cardiovascular Pharmacology 22 (Suppl 4): S1 S14 (1993).35Suzuki, et al. "Hemoglobin Augmentation of Interleukin-1β-Induced Production of Nitric Oxide in Smooth-Muscle Cells" J. Neurosurg 81: 895-901 (1994).36 *Suzuki, et al. Hemoglobin Augmentation of Interleukin 1 Induced Production of Nitric Oxide in Smooth Muscle Cells J. Neurosurg 81: 895 901 (1994).37Zayek, et al. "Treatment of Persistent Pulmonary Hypertension in the Newborn Lamb by Inhaled Nitric Oxide:" J. of Pediatrics 122(5 Part 1): 743-750 (1993).38 *Zayek, et al. Treatment of Persistent Pulmonary Hypertension in the Newborn Lamb by Inhaled Nitric Oxide: J. of Pediatrics 122(5 Part 1): 743 750 (1993).* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS8283337Feb 22, 2008Oct 9, 2012Next21 K.K.Therapeutic or prophylactic agent for vasoconstrictionUS8906855Aug 9, 2013Dec 9, 2014Vivacelle Bio, Inc.Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuriesUS9387162Nov 21, 2013Jul 12, 2016Vivacelle Bio, Inc.Methods and compositions for treating conditions related to lack of blood supply, shock, and neuronal injuriesUS9439855Nov 6, 2014Sep 13, 2016Vivacelle Bio, Inc.Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuriesUS9622968Nov 6, 2014Apr 18, 2017Vivacelle Bio, Inc.Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuriesUS20100035837 *Feb 22, 2008Feb 11, 2010Next21 K.K.Therapeutic or prophylactic agent for vasoconstrictionUS20100196461 *Jan 29, 2010Aug 5, 2010Simpkins Cuthbert OResuscitation fluid* Cited by examinerClassifications U.S. Classification514/761, 514/759, 424/718International ClassificationA61K9/08, A61K47/06, A61K9/00, A61K31/02Cooperative ClassificationA61K9/0026, A61K31/02European ClassificationA61K31/02, A61K9/00M5FLegal EventsDateCodeEventDescriptionOct 13, 1995ASAssignmentOwner name: ALLIANCE PHARMACEUTICAL CORP., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FLAIM, STEPHEN F.;REEL/FRAME:007672/0684Effective date: 19951004Jun 1, 1999ASAssignmentOwner name: ALLIANCE PHARMACEUTICAL CORP., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RIESS, JEAN G.;REEL/FRAME:009987/0892Effective date: 19990528Jun 5, 2000ASAssignmentOwner name: ALLIANCE PHARMACEUTICAL CORP., CALIFORNIAFree format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:IMPERIAL BANK;REEL/FRAME:010881/0519Effective date: 20000511Aug 24, 2000ASAssignmentOwner name: PFC THEAPUTICS, LLC, ILLINOISFree format text: SECURITY INTEREST;ASSIGNOR:ALLIANCE PHARMACEUTICAL CORP;REEL/FRAME:011170/0576Effective date: 20000519Aug 23, 2001FPAYFee paymentYear of fee payment: 4Oct 9, 2002ASAssignmentOwner name: SDS MERCHANT FUND, L.P., CONNECTICUTFree format text: SECURITY AGREEMENT;ASSIGNOR:ALLIANCE PHARMACEUTICAL CORP.;REEL/FRAME:013362/0076Effective date: 20021004Oct 10, 2002ASAssignmentOwner name: SDS MERCHANT FUND, L.P., CONNECTICUTFree format text: SECURITY AGREEMENT;ASSIGNOR:ALLIANCE PHARMACEUTICAL CORP.;REEL/FRAME:013372/0372Effective date: 20021004Owner name: CCL FUND, LLC C/O CASTLE CREEK LIFESCIENCE PARTNERFree format text: SECURITY AGREEMENT;ASSIGNOR:ALLIANCE PHARMACEUTICAL CORP.;REEL/FRAME:013372/0372Effective date: 20021004Owner name: CC LIFESCIENCE, LTD. C/O CASTLE CREEK LIFESCIENCEFree format text: SECURITY AGREEMENT;ASSIGNOR:ALLIANCE PHARMACEUTICAL CORP.;REEL/FRAME:013372/0372Effective date: 20021004Owner name: CASTLE CREEK HEALTHCARE INVESTORS, LLC C/O CASTLEFree format text: SECURITY AGREEMENT;ASSIGNOR:ALLIANCE PHARMACEUTICAL CORP.;REEL/FRAME:013372/0372Effective date: 20021004Owner name: BROWN SIMPSON PARTNERS I, LTD., NEW YORKFree format text: SECURITY AGREEMENT;ASSIGNOR:ALLIANCE PHARMACEUTICAL CORP.;REEL/FRAME:013372/0372Effective date: 20021004Jun 19, 2003ASAssignmentOwner name: ALLIANCE PHARMACEUTICAL CORP., CALIFORNIAFree format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:SDS MERCHANT FUND, L.P., AS COLLATERAL AGENT;REEL/FRAME:014146/0166Effective date: 20030618Jun 20, 2003ASAssignmentOwner name: ALLIANCE PHARMACEUTICAL CORP., CALIFORNIAFree format text: RELEASE OF SECURITY INTEREST;ASSIGNORS:BROWN SIMPSON PARTNERS I, LTD.;SDS MERCHANT FUND, L.P.;CASTLE CREEK HEALTHCARE INVESTORS, LLC;AND OTHERS;REEL/FRAME:014154/0571Effective date: 20030618May 6, 2004ASAssignmentOwner name: PFC THERAPEUTICS, LLC, CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLIANCE PHARMACEUTICAL CORP.;REEL/FRAME:015302/0480Effective date: 20040330Sep 9, 2005FPAYFee paymentYear of fee payment: 8Oct 12, 2009REMIMaintenance fee reminder mailedMar 10, 2010LAPSLapse for failure to pay maintenance feesApr 27, 2010FPExpired due to failure to pay maintenance feeEffective date: 20100310RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services